Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Other Non-Current Liabilities (2016 - 2025)

Historic Other Non-Current Liabilities for Guided Therapeutics (GTHP) over the last 12 years, with Q3 2025 value amounting to $79000.0.

  • Guided Therapeutics' Other Non-Current Liabilities rose 29500.0% to $79000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $79000.0, marking a year-over-year increase of 29500.0%. This contributed to the annual value of $118000.0 for FY2024, which is N/A changed from last year.
  • According to the latest figures from Q3 2025, Guided Therapeutics' Other Non-Current Liabilities is $79000.0, which was up 29500.0% from $60000.0 recorded in Q2 2025.
  • Guided Therapeutics' 5-year Other Non-Current Liabilities high stood at $118000.0 for Q4 2024, and its period low was -$24000.0 during Q2 2022.
  • Moreover, its 4-year median value for Other Non-Current Liabilities was $30000.0 (2021), whereas its average is $39307.7.
  • Per our database at Business Quant, Guided Therapeutics' Other Non-Current Liabilities tumbled by 18275.86% in 2022 and then surged by 40000.0% in 2025.
  • Over the past 4 years, Guided Therapeutics' Other Non-Current Liabilities (Quarter) stood at $32000.0 in 2021, then crashed by 115.62% to -$5000.0 in 2022, then surged by 2460.0% to $118000.0 in 2024, then plummeted by 33.05% to $79000.0 in 2025.
  • Its last three reported values are $79000.0 in Q3 2025, $60000.0 for Q2 2025, and $66000.0 during Q1 2025.